L Bertoletti1,2,3,4, P Robin4,5,6, L Jara-Palomares7, C Tromeur4,8,9, J Pastre4,10, N Prevot-Bitot4,11,12, T Mouneh4,13, G Le Gal4,14, P-Y Salaun4,5,6. 1. Service de Médecine Vasculaire et Thérapeutique. 2. INSERM, UMR1059, Equipe Dysfonction Vasculaire et Hémostase, Université Jean-Monnet. 3. INSERM, CIC-1408, CHU Saint-Etienne, Saint-Etienne. 4. F-CRIN INNOVTE network, St-Etienne. 5. Service de Médecine Nucléaire, CHRU de Brest. 6. GETBO EA3878, Université de Bretagne Occidentale, Brest, France. 7. Department of Pneumonology, Medical Surgical Unit of Respiratory Diseases, Instituto de Biomedicina de Sevilla (IBiS), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Hospital Universitario Virgen del Rocío, Seville, Spain. 8. Service de Pneumologie, CHRU de Brest. 9. GETBO EA3878, Université de Bretagne Occidentale, Brest. 10. Service de pneumologie, Hôpital européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris. 11. Service de Médecine Nucléaire. 12. INSERM, UMR1059, Equipe Dysfonction Vasculaire et Hémostase, Université Jean-Monnet, Saint-Etienne. 13. Service d'Urgences adultes, Centre Vasculaire et de la Coagulation, CHU d'Angers, Angers, France. 14. Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.
Abstract
Essentials Patients at high-risk of occult cancer may benefit from extensive screening. We validated the RIETE cancer score in the MVTEP study. One in three patients were classified as high-risk, 10% of whom had cancer diagnosed. The RIETE score identifies a subgroup at high risk for cancer. SUMMARY: Background Most recent trials evaluating extensive screening strategies for occult cancer in patients with unprovoked venous thromboembolism have failed, because, among other reasons, of an overall low rate of occult cancer. The RIETE investigators recently proposed a score aimed at identifying a subgroup at higher risk. Methods We retrospectively computed the RIETE score for all patients included in the MVTEP study, which evaluated the accuracy of [¹⁸F]fluorodeoxyglucose-positron emission tomography in the screening of occult cancer in patients with unprovoked venous thromboembolism. Performance of the RIETE score was assessed according to the proportion of patients classified in each risk group, and the corresponding rates of cancer diagnosis. Results Among the 386 patients included in the analysis, 136 patients (35.3%) were classified as high risk by the RIETE score. Cancer was diagnosed in 16 (11.8%) of them, whereas it was diagnosed in nine (3.6%) of the 250 patients with a low RIETE cancer score: odds ratio of 3.6 (95% confidence interval [CI] 1.53-8.32). The area under the receiver operating characteristic curve was 0.63 (95% CI 0.51-0.74). Conclusion The RIETE score seems to be able to identify a subgroup at high risk for cancer (10%) in our specific dataset of patients with unprovoked venous thromboembolism.
Essentials Patients at high-risk of occult cancer may benefit from extensive screening. We validated the RIETE cancer score in the MVTEP study. One in three patients were classified as high-risk, 10% of whom had cancer diagnosed. The RIETE score identifies a subgroup at high risk for cancer. SUMMARY: Background Most recent trials evaluating extensive screening strategies for occult cancer in patients with unprovoked venous thromboembolism have failed, because, among other reasons, of an overall low rate of occult cancer. The RIETE investigators recently proposed a score aimed at identifying a subgroup at higher risk. Methods We retrospectively computed the RIETE score for all patients included in the MVTEP study, which evaluated the accuracy of [¹⁸F]fluorodeoxyglucose-positron emission tomography in the screening of occult cancer in patients with unprovoked venous thromboembolism. Performance of the RIETE score was assessed according to the proportion of patients classified in each risk group, and the corresponding rates of cancer diagnosis. Results Among the 386 patients included in the analysis, 136 patients (35.3%) were classified as high risk by the RIETE score. Cancer was diagnosed in 16 (11.8%) of them, whereas it was diagnosed in nine (3.6%) of the 250 patients with a low RIETE cancer score: odds ratio of 3.6 (95% confidence interval [CI] 1.53-8.32). The area under the receiver operating characteristic curve was 0.63 (95% CI 0.51-0.74). Conclusion The RIETE score seems to be able to identify a subgroup at high risk for cancer (10%) in our specific dataset of patients with unprovoked venous thromboembolism.
Authors: Luis Jara-Palomares; Remedios Otero; David Jimenez; Juan Manuel Praena-Fernandez; Carme Font; Conxita Falga; Silvia Soler; David Riesco; Peter Verhamme; Manuel Monreal Journal: PLoS One Date: 2018-03-20 Impact factor: 3.240
Authors: Frits I Mulder; Marc Carrier; Frederiek van Doormaal; Philippe Robin; Hans-Martin Otten; Pierre-Yves Salaun; Harry R Büller; Grégoire Le Gal; Nick van Es Journal: J Thromb Haemost Date: 2020-08-04 Impact factor: 5.824